Artesunate (Artesunate Amivas®). HTA ID: 24019

Assessment Status Rapid Review complete
HTA ID 24019
Drug Artesunate
Brand Artesunate Amivas®
Indication For the initial treatment of severe malaria in adults and children.
Assessment Process
Rapid review commissioned 29/05/2024
Rapid review completed 26/06/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that IV Artesunate Amivas® not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.